

RESEARCH ARTICLE

Open Access



β -arrestin 1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells

Evelina Miele^{1,2}, Agnese Po³, Federica Begalli³, Laura Antonucci³, Angela Mastronuzzi², Carlo Efsio Marras⁴, Andrea Carai⁴, Danilo Cucchi³, Luana Abballe⁵, Zein Mersini Besharat⁵, Giuseppina Catanzaro⁵, Paola Infante¹, Lucia Di Marcotullio³, Gianluca Canettieri³, Enrico De Smaele⁵, Isabella Screpanti^{1,3}, Franco Locatelli^{2,7} and Elisabetta Ferretti^{5,6*} 

Abstract

Background: Aberrant Sonic Hedgehog/Gli (Hh/Gli) signaling pathway is a critical regulator of Sonic hedgehog medulloblastoma (SHH-MB). Cancer stem cells (CSCs), thought to be largely responsible for tumor initiation, maintenance, dissemination and relapse, have been identified in SHH-MB. Since we previously demonstrated that Hh/Gli signaling controls CSCs features in SHH-MB and that in these tumors miR-326 is down regulated, here we investigated whether there is a functional link between Hh/Gli signaling and miR-326.

Methods: We evaluated β -arrestin 1 (*Arb1*) and its intragenic miR-326 levels in CSCs derived from SHH-MB. Subsequently, we modulated the expression of *Arb1* and miR-326 in CSCs in order to gain insight into their biological role. We also analyzed the mechanism by which *Arb1* and miR-326 control Hh/Gli signaling and self-renewal, using luciferase and protein immunoprecipitation assays.

Results: Low levels of *Arb1* and miR-326 represent a feature of CSCs derived from SHH-MB. We observed that re-expression of *Arb1* and miR-326 inhibits Hh/Gli signaling pathway at multiple levels, which cause impaired proliferation and self-renewal, accompanied by down regulation of *Nanog* levels. In detail, miR-326 negatively regulates two components of the Hh/Gli pathway the receptor Smoothed (Smo) and the transcription factor Gli2, whereas *Arb1* suppresses the transcriptional activity of Gli1, by potentiating its p300-mediated acetylation.

Conclusions: Our results identify a new molecular mechanism involving miR-326 and *Arb1* as regulators of SHH-MB CSCs. Specifically, low levels of *Arb1* and miR-326 trigger and maintain Hh/Gli signaling and self-renewal.

Keywords: CSCs, Medulloblastoma, *Arb1*, Gli1 acetylation, miR-326, Hh/Gli signaling

Background

Tumor mass is composed by heterogeneous cell population including a subset of cells with stem-like characteristics called “cancer stem cells” (CSCs). CSCs could trigger tumor formation, drive resistance to conventional therapeutics and underlie patient relapse [1, 2]. Indeed,

stem cell signatures have been associated with poor prognosis in various tumors [1, 3–7]. CSCs have also been identified in medulloblastoma (MB) [8], the most common pediatric malignant brain tumor and a leading cause of cancer-related morbidity and mortality in childhood [9].

Medulloblastoma has been recently classified in 4 molecular subgroups and sonic-hedgehog-driven medulloblastoma (SHH-MB) is the second most common, accounting for 27% of all MBs. They represent an intermediate prognosis subgroup, with overall survival rates

* Correspondence: elisabetta.ferretti@uniroma1.it

⁵Department of Experimental Medicine Sapienza University, Viale Regina Elena, 291 - 00161, 00161 Rome, Italy

⁶Neuromed Institute, 86077 Pozzilli, Italy

Full list of author information is available at the end of the article



ranging from ~35% to ~80% [10]. Recurrence is a common event in SHH-MBs (30%) making the treatment challenging [11].

MB-associated Sonic Hedgehog/Gli (Hh/Gli) pathway deregulation is due to either canonical or non-canonical mechanisms. The canonical Hh/Gli pathway activation is modulated by the receptor Patched (Ptch) that suppresses the activity of Smoothened (Smo) [12, 13]. The binding of SHH protein ligand to Ptch relieves Smo suppression, leading to Hh/Gli activation that culminates in Gli2 transcription factor activation and subsequent translocation to the nucleus [13–15]. Gli2 is able to enhance the transcription of Hh/Gli target genes, including Ptch1 and the transcription factor Gli1, main effector of the signaling. Thus, mutations/focal deletions or amplifications of genes encoding pathway components, such as Ptch1, Smo, and Gli2 are well-recognized oncogenic events in SHH-MBs. On the other hand, non-canonical Hh/Gli activation mechanisms have been described, involving post-transcriptional modification of Gli1, histone methylation, p53/17p deletion and PI3K/Akt/S6 K aberrant activation [9, 16–22].

microRNAs (miRNAs) are major regulators of Hh/Gli signaling [23] and we have previously shown that miR-326 is downregulated in SHH-MBs where it inhibits Smo [23]. Recent evidence highlighted the crucial role of miRNAs also in CSCs [24]. The pivotal role of Hh/Gli pathway in controlling CSCs maintenance, including SHH-MB, has already been demonstrated [25–28].

We have previously isolated and characterized MB CSCs from mouse model of SHH-MB [26]. Such CSCs were capable to grow as oncospheres in stem cell-medium and expressed the stemness marker Nanog under Hh/Gli transcriptional regulation [26].

Since a thorough understanding of the molecular mechanisms that govern the maintenance of CSCs is necessary to unveil SHH-MB biology/behavior we decided to further investigate the Hh/Gli-miR-326 network in SHH-MB CSCs context.

Here we show that miR-326 and its host gene *Arrb1* are both down regulated in CSCs derived from SHH-MB, where they act as negative regulators of self-renewal. Indeed, their expression inhibits Hh/Gli signaling at multiple levels: *Arrb1* potentiates p300-mediated Gli1 inhibitory acetylation and miR-326 targets Smo and Gli2.

Methods

Animals

Murine CSCs were isolated, as previously reported [26] from Ptch1+/- mice model of SHH-MB (The Jackson Laboratory, Bar Harbor, ME, USA) maintained in the Molecular Medicine Department Animal Facility at Sapienza University of Rome. Experiments were carried

out on CSCs derived from 6 different Ptch1+/- mice. All experiments were performed in accordance with national guidelines and regulations, and with the approval of the animal care and use committees of our institution.

CSC cultures, oncosphere-forming assay, differentiation, over-expression, silencing and proliferation assay

CSCs were cultured as previously reported [26]. Selective medium (SM) was used for CSCs enrichment, consisting of DMEM/F12 with B27 supplement without vitamin A and 2 mg/ml heparin, 0,6% glucose, 60 mg/ml N-acetyl-L-cysteine, 25 µg/ml insulin, 20 ng/ml EGF, 20 ng/ml bFGF.

Oncosphere-forming assay was performed as previously described [26]. In detail, cells were plated at clonal density (1–2 cells/mm²) into 96-well plates and cultured in SM.

To induce differentiation, oncospheres were mechanically dissociated and plated into D-poly-lysine coated dishes in differentiation medium (DFM): DMEM/F12 with N2 supplement and 2 mg/ml heparin, 0,6% glucose, 60 mg/ml N-acetyl-L-cysteine, 1% Calf Serum and retinoic acid 2 µM.

Amaxa nucleofector (Lonza) was used to transfect plasmids according to manufacturer's procedure. miR-326 vector and its negative control were purchased from GeneCopoeia (MmiR3333-MR01); *Arrb1* vector was obtained from Addgene [29]. For rescue experiments, cells were transfected with both miR-326 vector and SmoM2 and Gli2-Flag plasmid vectors [23, 26].

Silencing of *Arrb1* was performed with HiPerFect (Qiagen) using ON-TARGETplus SMARTpool (L40976–00-005 mouse *ARRB1*) from Thermo Scientific, after testing each single siRNA of the pool, alone or in combination, for its specificity to avoid OFF-target effects.

Proliferation of MB CSCs was evaluated by BrdU incorporation, as previously described [30]. Cells were counted in triplicate and the number of BrdU-positive nuclei was annotated. MB CSCs growth was measured by MTS (Promega) assay according to manufacturer's instructions. Each sample was measured in triplicate and repeated at least three times.

HEK293T cells were cultured and transfected as previously described [26] with the indicated plasmids as in [31].

Western blot and immunoprecipitation assays

Cells were lysed using RIPA buffer (Tris-HCl pH 7.6 50 mM, deoxycholic acid sodium salt 0.5%, NaCl 140 mM, NP40 1%, EDTA 5 mM, NaF 100 mM, sodium pyrophosphate 2 mM and protease inhibitors). Lysates were separated on 8% acrylamide gel and immunoblotted using standard procedures. The following antibodies were

used: anti-Arrb1 K-16 (sc-8182; Santa Cruz Biotechnology), anti-Nanog (Cosmo Bio Co, Japan), anti-Actin I-19 (sc-1616; Santa Cruz Biotechnology), anti- β -III-Tubulin (MAB 1637 Millipore), anti-Gli1 H-300 (sc-20,687; Santa Cruz Biotechnology), anti-acetyl-Gli1 (Lys518) (Eurogentec) [32], anti-p300 C-20 (sc-585; Santa Cruz Biotechnology), anti-FLAG M2-Peroxidase (HRP) (A8592 Sigma), anti-HA (sc-7392 Santa Cruz), anti-Gli2 H-300 (sc-28,674; Santa Cruz Biotechnology), anti-Smo N-19 (sc-6366; Santa Cruz Biotechnology), anti-Sox2 (MAB4343 Millipore). HRP-conjugated secondary antibodies (Santa Cruz Biotechnology) were used in combination with enhanced chemo-luminescence (ECL Amersham).

For immunoprecipitation assay antibody sources and concentrations used were: Protein G Plus-Agarose (sc-2002; Santa Cruz Biotechnology); anti-FLAG M2 Affinity Gel (Sigma A2220, IP 30 [1]), anti-FLAG M2-Peroxidase (HRP) (A8592 Sigma, western blotting 1:5000), anti-HA (sc-7392 Santa Cruz, 1:1000); anti-myc-HRP.

Immunofluorescence

CSCs were plated on D-poly-lysine-coated Lab-Tek chamber slides (coverslips) and allowed to adhere for

3 h. For the staining of differentiated cells, cells were cultured on D-poly-lysine-coated coverslips in DFM for 48 h. Cells were fixed with 4% paraformaldehyde for 20 min at room temperature, incubated in blocking solution (5% normal goat serum (NGS), 1% BSA, 0.1% Triton X-100) and stained overnight with primary antibodies diluted in blocking solution and 2 h with secondary antibodies. Primary antibodies were anti-Nanog (Cosmo Bio Co, Japan), anti-Nestin (AB6142, Abcam) and anti-Gli1 (#2643 Cell Signaling Technology Inc); 488-conjugated anti-mouse and anti-rabbit secondary antibodies were purchased from Molecular Probes (Invitrogen, Eugene, OR). Nuclei were counterstained with Hoechst reagent. Cover slips were mounted with fluorescence mounting medium (S3023, Dako). Images were acquired with Carl Zeiss microscope (Axio Observer Z1) using Apotome technology and AxioVision Digital Image Processing Software.

RNA isolation and qRT-PCR

Unless otherwise indicated, reagents and equipment were purchased from Thermo Fisher Scientific. Total RNA was purified using Trizol and treated with DNase. One μ g was reverse transcribed using random primers




Fig. 1 Low levels of miR-326 characterize SHH-MB CSCs. **a** Left: Western blot (WB) analysis of endogenous Hh/Gli and stemness markers levels in pre-oncosphere cell population (T0) and oncospheres (CSCs) derived Ptch1+/- mice model of SHH-MB. Loading control (LC): Actin. Right: Immunofluorescence of nuclear Hoechst (blue) staining with Nanog or Nestin (green) in CSCs. Scale bar: 10 μ m. **b** miR-326 expression levels in MB cells grown in SM (CSCs) vs pre-oncosphere cell population (T0) are expressed in arbitrary units (AU). Bar graphs represent mean \pm S.D. from three independent experiments. * $p < 0.05$. **c** Left panel: WB analysis of endogenous Hh/Gli, stemness and differentiation markers levels in CSCs grown as oncospheres in SM and exposed to differentiation stimuli (DFM). LC: Actin. Right panel: Immunofluorescence of nuclear Hoechst (blue) staining with Nanog or Gli1 (green) in CSCs grown in SM or DFM. Scale bar: 10 μ m. **d** miR-326 expression levels in MB cells grown in SM (CSCs) or in DFM

and SuperScript II as previously described [23]. Quantitative RT-PCR (qRT-PCR) analysis was performed using the ABI Prism 7900HT Sequence Detection System, using the “best coverage” TaqMan gene expression assays, specific for each analyzed mRNA, according to manufacturer’s protocol. Each amplification reaction was performed in triplicate, and the average of the three threshold cycles was used to calculate the amount of transcripts in the sample (SDS 2.3 software). mRNA quantification was expressed, in arbitrary units, as the ratio of the sample quantity to the

calibrator or to the mean values of control samples. All data were normalized to the mean value of three endogenous controls: GusB, β 2-microglobulin and HPRT.

miR-326 expression was normalized to RNU6B: both were measured using TaqMan microRNA assays according to manufacturer’s instructions.

Luciferase and mutagenesis assays

The putative miR-326 binding site on Gli2 3’UTR was identified by bioinformatics analysis using the combination




Fig. 2 *Arrb1* is down regulated in SHH-MB CSCs. **a** miR-326 intragenic localization in the first intron of the *Arrb1* gene on murine chromosome 7 and human chromosome 11. **b** WB (Left panel) of *Arrb1* and *Nanog* levels in SM (CSCs) vs pre-oncosphere cell population (T0). mRNA expression (Right panel) analysis of *Arrb1* (*Arrb1*) levels MB cells grown in CSCs vs T0. Bar graphs represent mean \pm S.D. from three independent experiments. * $p < 0.05$. **c** *Arrb1* and *Nanog* expression levels in CSCs grown as oncospheres in SM and exposed to differentiation stimuli (DFM). LC: Actin. **d** Oncosphere forming assay (left panel) and bromodeoxyuridine (BrdU) uptake (right panel) in CSCs after ectopic expression of miR-326 and *Arrb1*. Data represent mean \pm S.D. from five independent experiments. * $p < 0.05$

between miRanda and Target Scan algorithm (<http://www.microrna.org/microrna/home.do>). The entire 3'UTR region of mouse Gli2 was purchased from GeneCopoeia in pEZX-MT01 vector (MmiT025993-MT01). This construct was used to obtain the mutant derivate lacking the entire miR-326 binding sequence, using the QuickChange XL Site-Directed Mutagenesis kit (Agilent Technologies). MB

CSCs were transfected with 3'UTR plasmids of wild type Gli2-3'UTR or mutant Gli2-3'UTR and miR-326 vector or the empty control with Fugene6 Transfection Reagent (Promega). For analysis of luciferase activity from the Gli-responsive reporter in presence of Arrb1, cells were transfected with Gli-responsive reporter (Gli8x_luc) and with a wild-type Gli1 vector (Gli1 wt) or a Gli1 mutant




Fig. 3 (See legend on next page.)

(See figure on previous page.)

Fig. 3 miR-326 inhibits stemness by targeting Hh/Gli signaling. **a** miR-326 levels (left panel) and Gli2 and Smo western blot analysis (right panel) in CSCs overexpressing miR-326. * $p < 0.05$. LC: Actin. **b** Upper panel: putative miR-326 binding site on the Gli2 3'UTR (miRanda algorithm). Lower panel: luciferase activity in CSCs overexpressing miR-326 and transfected with either the Gli2 wild type 3'UTR vector (Gli2) or the Gli2mut derivative, lacking the miR-326 binding site. Nanog 3'UTR vector (no putative miR-326 binding sites) as negative control. Results are expressed as a ratio vs scrambled miRNA vector-transfected cells (Ctr). Data represent mean \pm S.D. from three independent experiments. * $p < 0.05$. **c** Histograms showing mRNA expression levels of the indicated Hh target genes in CSCs overexpressing miR-326 compared to control empty vector (Ctr). Data represent mean \pm S.D. from three independent experiments. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.005$. **d** Oncosphere forming assay in CSCs after ectopic expression of miR-326. Data represent mean \pm S.D. from three independent experiments. * $p < 0.05$. **e** WB analysis of endogenous Nanog in CSCs overexpressing miR-326 or scramble miRNA as control (Ctr). LC: actin. **f** BrdU uptake in MB CSCs after ectopic expression of miR-326. Data represent mean \pm S.D. from three independent experiments. * $p < 0.05$. **g** Cell growth assessed through MTT assay in CSCs overexpressing miR-326 together or not with the co-expression of SmoM2 and Gli2-Flag (Smo and Gli2) plasmid vectors. Data represent mean \pm S.D. from three independent experiments. * $p < 0.05$. **h** Oncosphere forming assay in CSCs overexpressing miR-326 together or not with the co-expression of SmoM2 and Gli2-Flag (Smo and Gli2) plasmid vectors. Data represent mean \pm S.D. from three independent experiments. * $p < 0.05$

(Gli1 K518R) [20], together with the Arrb1 plasmid or an empty vector as control. In all luciferase experiments pRL-CMV-Renilla Luciferase control vector was used. After 24 h cells were collected and tested with dual luciferase-assay (Promega). All luciferase activity data are presented as mean \pm S.D. of values from at least three experiments in triplicate.

For mutagenesis of miR-326 binding site on Gli2–3'UTR, the following primers were used:

Fw: CCCAGGGCAGCAAACCTCAGGACCAACTCCAAA
Rw: TTTGGAGTTGGTCCTGAGTTTGCTGCCCTGGG

SHH-MB samples

Surgical specimens used in this study originate from a cohort of patients, recruited with Institutional Review Board approval of the contributing Centers, as previously described [23, 33]. For this study 10 ng of cDNA from each MB was analyzed for the expression levels of genes specific for SHH-MB molecular classification (as described in [10, 34]).

In detail for ARRB1 and pri-miR-326 expression analysis $n = 17$ cDNA of human SHH MBs and 10 adult cerebella as control were evaluated by RT-PCR and statistical differences were assessed by Mann–Whitney U test for non-parametric values using GraphPad Prism 6 software. Regression analysis was performed using GraphPad Prism 6 software.

Statistical analysis

Statistical analysis of cellular experimental triplicates was performed using StatView 4.1 software (Abacus Concepts, Berkeley, CA). Statistical differences were analysed by Mann–Whitney U test for non-parametric values and a p -value of 0.05 was considered significant. The results are expressed as mean \pm S.D. from an appropriate number of experiments as indicated in the respective figure legends.

Results

Low levels of miR-326 characterize SHH-MB CSCs

We have previously identified miR-326 as a negative regulator of Hh/Gli signaling in cerebellar granule cell progenitors (GCPs) (23). Next from SHH-MB of Ptc1 +/- mice [28], we isolated and characterized CSCs capable to grow as oncospheres in stem cell-medium [26]. In this study we aimed to investigate the Hh/Gli signaling and miR-326 network in SHH-MB CSCs context. First we observed that Hh/Gli signaling components, including Gli1, Gli2 and Smo, together with stemness markers Nanog, Sox2 and Nestin were enriched in CSCs respect to SHH-MB Ptc1 pre-oncosphere cell populations (T0) (Fig. 1a). CSCs were also characterized by low levels of miR-326 in respect to T0 (Fig. 1b). When shifted to differentiation medium (DFM), CSCs expressed the neuronal marker β -III-tubulin and down regulated the expression of Hh/Gli pathway components and stemness markers (Fig. 1c) while miR-326 expression increased (Fig. 1d).

Overall our findings showed that miR-326 is inversely expressed respect to Hh/Gli signaling and stemness in SHH-MB CSCs.

Arrb1 is down regulated in SHH-MB CSCs

miR-326 coding gene resides in the first intron of the host gene *Arrb1* in mouse chromosome 7q and in human chromosome 11q (Fig. 2a). Notably, miR-326 and *Arrb1* share common regulatory sequences acting as a single transcriptional unit [35]. Together these data prompted us to investigate *Arrb1* in CSCs. We found low *Arrb1* expression levels of both mRNA and protein (Fig. 2b), while *Arrb1* was expressed in differentiated CSCs (DFM) (Fig. 2c). These results highlighted that low levels of the transcription unit *Arrb1* and *miR-326* are associated with SHH-MB CSCs. The ectopic re-expression of *Arrb1* and miR-326 impaired their clonogenic potential (expressed as the percentage of oncospheres formation) and their proliferation rate (Fig. 2d).

These results support a role for Arrb1 and miR-326 in the establishment and maintenance of a “differentiated cell-phenotype”.

miR-326 and Arrb1 impair stemness through suppression of Hh/Gli pathway at multiple levels.

The observation of low levels of miR-326 and Arrb1 in CSCs derived from SHH-MBs suggests that they can

negatively regulate the major pro-proliferative signaling in these cells, namely the Hh/Gli pathway [25–28].

Here we showed that miR-326 re-expression in SHH-MB CSCs inhibited the Hh/Gli signaling at both receptor and transcription factor levels. Indeed, miR-326 reduced Smo protein, as already described in undifferentiated GCPs [23], but also downregulated Gli2 levels (Fig. 3a). In silico analysis revealed the presence of putative miR-326




Fig. 4 (See legend on next page.)

(See figure on previous page.)

Fig. 4 *Arrb1* mediates acetylation of Gli1. **a** *Arrb1* and Gli1 protein levels in CSCs transfected with the *arrb1*-HA plasmid and analyzed 48 h after transfection. LC: Actin. **b** WB analysis of endogenous *Arrb1*, Gli1 and its acetylated form (Gli1-ac) in CSCs cultured in SM in DFM for the indicated time points. LC: Actin. **c** *Arrb1*, Gli1 its acetylated form (Gli1-ac) protein levels in CSCs transfected with the *arrb1*-HA plasmid and analyzed 8 h after transfection. LC: Actin. **d** *Arrb1*, acetylated Gli1 (Gli1-ac) and p300 protein levels in CSCs transfected with control siRNA (siCtr) or *Arrb1* siRNA (si*Arrb1*) cultured for 12 h in DFM. LC: Actin. **e** HEK293T cells were transfected with the *Arrb1*-HA, Gli1-Flag and p300-HA plasmids, alone or in combination. *Left panel*: whole cell extracts were immunoprecipitated with anti-Flag agarose beads and immunoblotted with anti-HA, anti-Flag and anti-Gli1-ac antibodies. As negative controls, beads were pre-blocked with excess Flag peptide (0.1 mg/ml). *Right panel*: 2.5% of the immunoprecipitated cell lysates (input) were immunoblotted with the indicated antibodies. These experiments show that *Arrb1* forms a complex with p300 and Gli1. **f** Luciferase activity of Gli-responsive reporter (Gli8x_{luc}) in CSCs co-transfected with a wild-type Gli1-flag expression vector (Gli1 wt) or a Gli1K/R mutant (Gli1 K518R) together with the *arrb1*-HA or an empty vector as control. **p* < 0.05 vs Empty; ***p* < 0.05 vs Gli1 wt. **g** *Left panel*: Oncosphere forming assay in CSCs after ectopic expression of *Arrb1*. Data represent mean ± S.D. from three independent experiments. **p* < 0.05. *Right panel*: WB analysis of endogenous Nanog along with ectopic *Arrb1* in CSCs overexpressing *Arrb1* or empty vector as control (Ctr). LC: actin. **h** BrdU uptake in CSCs after ectopic expression of *Arrb1*. Data represent mean ± S.D. from three independent experiments. **p* < 0.05

binding sites in the Gli2-3'UTR (Fig. 3b *upper panel*). miR-326 overexpression repressed the activity of a reporter construct carrying the mouse Gli2-3'UTR (Fig. 3b, *bottom panel*) but had no effect on either Gli2-3'UTR construct with mutated miR-326-binding sites or on the unrelated Nanog-3'UTR reporter (Fig. 3b, *bottom panel*). Consistent with an inhibitory role of miR-326 on Hh/Gli signaling we observed that the overexpression of miR-326 impaired the expression levels of the transcription target genes of the Hh/Gli pathway as defined by KEGG pathway analysis and literature *Gli1*, *Ptch1*, *Hhip1*, *Mycn*, *Ccnd1*, *Ccnd2*, *Bcl2*, *Nanog*, *Srpf1* [36, 37] (Fig. 3c).

Next, since Hh/Gli pathway controls CSCs [25] and their stemness marker Nanog [26] we investigated whether miR-326 re-expression impairs self-renewal and cell proliferation rate in our cellular model. Indeed, overexpression of miR-326 in SHH-MB CSCs significantly impaired their clonogenic ability (Fig. 3d). These results are consistent with a concomitant suppression of Nanog protein expression (Fig. 3e) and impairment of proliferation rate (Fig. 3f). In accordance with miR-326-mediated targeting of Smo and Gli2, overexpression of plasmid vectors harboring the open reading frame of these genes together with miR-326, rescued the miRNA-induced inhibition of cell growth (Fig. 3g) and clonogenic activity (Fig. 3h). These results highlighted that low miR-326 maintains CSCs features by controlling Hh/Gli signaling components.

Hence we evaluated the function of the host gene of miR-326, *Arrb1*, in SHH-MB CSCs. *Arrb1* encodes a multifunctional adaptor and scaffold protein regulating several signaling pathways critically involved in cell development in both physiological and pathological (i.e. cancer) contexts [38]. *Arrb1* was reported to function as a protein that interacts with the histone acetyl-transferase (HAT) facilitating its recruitment to target histones, with consequent increased chromatin acetylation and transcription activation [31, 39]. We previously reported that Gli transcription factors activity is regulated by acetylation via the acetyl-transferase p300 [20, 32].

Interestingly, we observed that Gli1 protein levels sharply decreased in CSCs overexpressing *Arrb1* (Fig. 4a) and in response to DFM (Fig. 4b). Notably, Gli1 downregulation was preceded by an early increase of its acetylated form (Fig. 4b and c).

These results show that shifting SHH-MB CSCs to DFM induces the expression of *Arrb1* and is linked to Gli1 acetylation, a modification that limits the activity of this transcription factor [20]. Since Gli1 acetylation is regulated by p300 [20] we sought to investigate the role of *Arrb1* in this regulatory mechanism. We discovered that Gli1 acetylation was strongly impaired by *Arrb1* knockdown (Fig. 4d). Moreover we show that *Arrb1* formed a complex with both p300 and Gli1 (Fig. 4e). To further link *Arrb1* to Gli1 acetylation and activity, we tested the effects of exogenously expressed *Arrb1* on transcriptional activation of a Gli-responsive luciferase reporter by wild-type Gli1 or the Gli1K518R acetylation defective mutant [20]. As shown in Fig. 4f, *Arrb1* inhibited the activity of wild type Gli1, whereas the Gli1K518R mutant was not affected. Taken together, these results indicated that *Arrb1* inhibits Hh/Gli signaling through the modulation of Gli1 K518 acetylation. Overexpression of *Arrb1* in CSCs significantly reduced clonogenicity (Fig. 4g left), Nanog protein levels (Fig. 4g right) and cell proliferation rate (Fig. 4h).

Altogether these results show that miR-326 and *Arrb1* inhibit CSCs self-renewal and proliferation by suppressing Hh/Gli signaling at multiple levels. Collectively, this data suggest that the previously described acetylation mechanism of Gli1 and Gli2 function [20] is a part of a regulatory *Arrb1*/p300-dependent circuitry in cancer context.

miR-326, pri-miR-326 and ARRB1 are coherently down regulated in human SHH-MBs

We previously reported that human SHH-MB expressed low levels of mature miR-326 [23, 33]. Taking in consideration our results in mouse models of SHH-MB we

evaluated *ARRB1* and *pri-miR-326* expression levels in primary tumors derived from SHH-MB patients. Here we found that *ARRB1* mRNA, as well as *pri-miR-326*, were significantly down-regulated in SHH-MBs when compared to adult cerebella (Fig. 5a and b) and their expression levels were highly correlated, as revealed by regression analysis (Fig. 5c).

Altogether these results showed that human SHH-MBs, characterized by an aberrant activation of the Hh/


Gli signaling pathway, displayed a coordinated downregulation of *ARRB1* and *miR-326*.


Discussion

We identified the down regulation of *miR-326* and its host gene *Arrb1* as a critical feature of CSCs derived from SHH-MB (Fig. 6). Re-expression of *miR-326* and *Arrb1* inhibits Hh/Gli pathway by targeting multiple activator components of this signaling *Smo*, *Gli2* and *Gli1* required for CSCs behavior. This conclusion is supported by at least two lines of evidence. First, low levels of *miR-326* and *Arrb1* characterized SHH-MB CSCs whereas CSCs in DFM re-express *miR-326* and *Arrb1* that leads to their differentiation and loss of stemness markers. Second, *Arrb1* and *miR-326* converge upon the Hh/Gli downstream signaling pathway that regulates cell growth and stemness. Indeed, we show that *miR-326* suppresses Hh/Gli signaling by targeting *Smo* and *Gli2*, and that *Arrb1* limits *Gli1* transcription activity by promoting p300-dependent *Gli1* acetylation further inhibiting Hh/Gli signaling.

miR-326 is a recognized tumor-suppressing miRNA, in fact among its targets there are *Gli2*, *Smo*, *Notch1*, *Notch2* and *Nob1* [23, 40–46]. *miR-326* has been already described down regulated in several tumors [40–42], including brain tumor, e.g. medulloblastoma itself [23] and glioblastoma [43–45] where it targets key molecules of gliomagenesis [43, 46] and its ectopic expression impaired the viability of both glioma cell lines and glioma stem-like cells [43]. Of note, *miR-326* levels have been shown to have a prognostic significance in glioblastoma patients [47].

In our study we focused on the role of *miR-326* and its host gene *Arrb1* in SHH-MB CSCs context. Previous studies have shown that *Arrb1* functions as an adaptor/scaffold protein that shuttles between the cytoplasm and the nucleus, where it interacts with *CREB* and with p300 acetyltransferase on the promoters of target genes to enhance H3 and H4 histones acetylation and gene expression [48–51]. Our observation that *Arrb1* promotes p300-mediated acetylation of *Gli1* is consistent with such described ability to facilitate p300-dependent acetylation [31, 39] and extends to a more direct modality to modulate gene expression in the nucleus. We previously reported that *Gli1* activity is regulated by acetylation [20, 32]. HDAC1-mediated deacetylation enhances *Gli1* transcriptional activity, whereas acetylation at specific lysine residues inhibits their function [20, 32]. We show here that p300 is the HAT involved and, more importantly, that *Arrb1* enhances this function. Thus, *Arrb1* targets *Gli1* and has a specific role in controlling Hh/Gli pathway and stemness. However we cannot exclude that such mechanism could involve other acetyltransferases, e.g. p300/CBP-associated factor (PCAF)





which has been reported to be able to interact with both Gli1 [52] and Arrb1 [53]. Similarly, the pleiotropic effect achievable by modulating protein acetylation may underlie other possible functions of Arrb1 in controlling other mechanisms of cell growth arrest [48].

Altogether our results indicate that miR-326 and Arrb1 encode a double signal (miRNA and hosting protein encoding gene) that cooperates to control SHH-MB, both in mouse models and in human MBs, through the modulation of morphogenetic signals Hh/Gli.

Conclusion

In conclusion, in our study we identified a new molecular mechanism involving miR-326 and Arrb1 as regulators of SHH-MB CSCs. We demonstrated that low levels of miR-326 and Arrb1 trigger and sustain Hh/Gli signaling activation and self-renewal in SHH-MBs. The re-expression of both elements of this locus is able to impair self-renewal and proliferation of SHH-MB CSCs converging on blunting Hh signaling at multiple levels. These findings contribute to the understanding of the SHH-MB biology/behavior unveiling a mechanism underlying the cancer stem cell maintenance.

Abbreviations

ARRB1: β -arrestin1 human; Arrb1: β -arrestin1 mouse; CSCs: Cancer stem cells; DFM: Differentiation medium; GCPs: Cerebellar granule cell progenitors; Gli1: Glioma associated oncogene homolog 1; Gli1-ac: Acetylated Gli1 form; Hh/Gli: Sonic Hedgehog/Gli; Ptch: Patched; SHH-MB: Sonic hedgehog medulloblastoma; SM: Selective medium; Smo: Smoothed

Acknowledgments

We thank Alberto Gulino, friend, mentor and colleague, who passed away while the manuscript was in preparation, for his inspiring vision and continued support.

Funding

This work was supported by grants from: Ministry of University and Research (PRIN: 20108XYHJS, FIRB: RBAP11WCRZ, PON: 1059, PON: 2464), Associazione Italiana Ricerca Cancro (AIRC, IG 14723), Sapienza University of Rome (C26G14F3KE), Ministry of Health and Istituto Italiano di Tecnologia. The funding bodies were not involved in study design, data collection, analysis and interpretation of data or writing of the manuscript.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The investigation on human tissues was approved by the Institutional Review Board of Bambino Gesù Hospital (Prot. N. 21LB; Study Number 730/2013). Written informed consent was obtained from all patients or legal representatives (as outlined by individual institutional review boards). Experiments on animals were performed in accordance with the Guidelines for Animal Care and Use of the National Institutes of Health (Ethical committee for animal experimentation Prot. N 03/2013, University of Rome Sapienza).

Authors' contributions

Designed the experiments: EM, EF, AP; Acquisition and analysis of data: EM, AP, FB, AM, CEM, AC, DC, LA, LAGC, PI and ZMB; Writing: EM, EF, FL; Interpretation of data: GC, LDM, EDS. and IS; Supervision: EF. All authors read and approved the final manuscript.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Center for Life NanoScience@Sapienza, Istituto Italiano di Tecnologia, 00161 Rome, Italy. ²Department of Hematology/Oncology and Stem Cell Transplantation, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy. ³Department of Molecular Medicine Sapienza University, 00161 Rome, Italy. ⁴Department of Neuroscience and Neurorehabilitation, Neurosurgery Unit, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy. ⁵Department of Experimental Medicine Sapienza University, Viale Regina Elena, 291 - 00161, 00161 Rome, Italy. ⁶Neuromed Institute, 86077 Pozzilli, Italy. ⁷Department of Pediatric Science, University of Pavia, Pavia, Italy.

Received: 13 December 2016 Accepted: 9 July 2017

Published online: 17 July 2017

References

- Mastronuzzi A, Miele E, Po A, Antonelli M, Buttarelli FR, Colafati GS, et al. Large cell anaplastic medulloblastoma metastatic to the scalp: tumor and derived stem-like cells features. *BMC Cancer*. 2014;14(1):262.
- Wang J, Wechsler-Reya RJ. The role of stem cells and progenitors in the genesis of medulloblastoma. *Exp Neurol*. 2014;260:69–73.
- Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. *Nat Genet*. 2008;40(5):499–507.
- Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, et al. Using a stem cell-based signature to guide therapeutic selection in cancer. *Cancer Res*. 2011;71(5):1772–80.
- Wang T, Ong C, Shi J, Srivastava S, Yan B, Cheng C, et al. Sequential expression of putative stem cell markers in gastric carcinogenesis. *Br J Cancer*. 2011;105(5):658–65.
- Bauer L, Langer R, Becker K, Hapfelmeier A, Ott K, Novotny A, et al. Expression profiling of stem cell-related genes in neoadjuvant-treated gastric cancer: a NOTCH2, GSK3B and β -catenin gene signature predicts survival. *PLoS One*. 2012;7(9):e44566.
- Vanner RJ, Remke M, Gallo M, Selvadurai HJ, Coutinho F, Lee L, et al. Quiescent Sox2+ cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. *Cancer Cell*. 2014;26(1):33–47.
- Manoranjan B, Wang X, Hallett RM, Venugopal C, Mack SC, McFarlane N, et al. FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells. *Stem Cells*. 2013;31(7):1266–77. doi:10.1002/stem.1401.
- Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature*. 2012;488(7409):49–56. doi:10.1038/nature11327.
- Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. *Acta Neuropathol*. 2012;123(4):473–84.
- Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho Y-J, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. *Lancet Oncol*. 2013;14(12):1200–7.
- Ocbina PJR, Anderson KV. Intraflagellar transport, cilia, and mammalian Hedgehog signaling: analysis in mouse embryonic fibroblasts. *Dev Dyn*. 2008;237(8):2030–8.
- Kim J, Kato M, Beachy PA. Gli2 trafficking links Hedgehog-dependent activation of Smoothened in the primary cilium to transcriptional activation in the nucleus. *Proc Natl Acad Sci*. 2009;106(51):21666–71.
- Corbit KC, Aanstad P, Singla V, Norman AR, Stainier DY, Reiter JF. Vertebrate Smoothened functions at the primary cilium. *Nature*. 2005;437(7061):1018–21.
- Rohatgi R, Milenkovic L, Scott MP. Patched1 regulates hedgehog signaling at the primary cilium. *Science*. 2007;317(5836):372–6.
- Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. *Nature*. 2012;488(7409):106–10. doi:10.1038/nature11329.
- Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. Novel mutations target distinct subgroups of medulloblastoma. *Nature*. 2012;488(7409):43–8. doi:10.1038/nature11213.
- Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, et al. An animal model of MYC-driven medulloblastoma. *Cancer Cell*. 2012;21(2):155–67. doi:10.1016/j.ccr.2011.12.021.
- Archer TC, Pomeroy SL. Medulloblastoma biology in the post-genomic era. *Future Oncol*. 2012;8(12):1597–604. doi:10.2217/fon.12.151.
- Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, et al. Histone deacetylase and Cullin3–RENKCTD11 ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. *Nat Cell Biol*. 2010;12(2):132–42.
- D'Amico D, Antonucci L, Di Magno L, Coni S, Sdruscia G, Macone A, et al. Non-canonical Hedgehog/AMPK-mediated control of polyamine metabolism supports neuronal and medulloblastoma cell growth. *Dev Cell*. 2015;35(1):21–35.
- Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell*. 2014;25(3):393–405.
- Ferretti E, De Smaele E, Miele E, Laneve P, Po A, Pelloni M, et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. *EMBO J*. 2008;27(19):2616–27. doi:10.1038/emboj.2008.172.
- Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. *Nat Cell Biol*. 2013;15(6):546–54. doi:10.1038/ncb2769.
- Justilien V, Fields A. Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells. *Clin Cancer Res*. 2015;21(3):505–13. doi:10.1158/1078-0432.CCR-14-0507.
- Po A, Ferretti E, Miele E, De Smaele E, Paganelli A, Canettieri G, et al. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. *EMBO J*. 2010;29(15):2646–58. doi:10.1038/emboj.2010.131.
- Schüller U, Heine VM, Mao J, Kho AT, Dillon AK, Han Y-G, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. *Cancer Cell*. 2008;14(2):123–34.
- Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourbonlous M, et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. *Cancer Cell*. 2008;14(2):135–45. doi:10.1016/j.ccr.2008.07.003.
- Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. *Science*. 1999;283(5402):655–61.
- Garg N, Po A, Miele E, Campese AF, Begalli F, Silvano M, et al. microRNA-17-92 cluster is a direct Nanog target and controls neural stem cell through Trp53inp1. *EMBO J*. 2013;32(21):2819–32. doi:10.1038/emboj.2013.214.
- Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, et al. A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. *Cell*. 2005;123(5):833–47. doi:10.1016/j.cell.2005.09.011.
- Coni S, Antonucci L, D'Amico D, Di Magno L, Infante P, De Smaele E, et al. Gli2 acetylation at lysine 757 regulates hedgehog-dependent transcriptional output by preventing its promoter occupancy. *PLoS One*. 2013;8(6):e65718.
- Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola M, et al. MicroRNA profiling in human medulloblastoma. *Int J Cancer*. 2009;124(3):568–77. doi:10.1002/ijc.23948.
- Miele E, Mastronuzzi A, Po A, Carai A, Alfano V, Serra A, et al. Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup. *Biomark Res*. 2015;3(1):1. doi:10.1186/s40364-015-0038-z.
- Monteys AM, Spengler RM, Wan J, Tecedor L, Lennox KA, Xing Y, et al. Structure and activity of putative intronic miRNA promoters. *RNA*. 2010;16(3):495–505.
- Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. *Curr Mol Med*. 2009;9:873–86. doi:10.2174/156652409789105570.
- Katoh Y, Katoh M. Hedgehog signaling pathway and gastrointestinal stem cell signaling network (review). *Int J Mol Med*. 2006;18(6):1019–24.
- DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. β -arrestins and cell signaling. *Annu Rev Physiol*. 2007;69:483–510.
- Parathath SR, Mainwaring LA, Fernandez LA, Guldal CG, Nahle Z, Kenney AM. beta-Arrestin-1 links mitogenic sonic hedgehog signaling to the cell cycle exit machinery in neural precursors. *Cell Cycle*. 2010;9(19):4013–24. doi:10.4161/cc.9.19.13325.
- Wu L, Hui H, Wang L-J, Wang H, Liu Q-F, Han S-X. MicroRNA-326 functions as a tumor suppressor in colorectal cancer by targeting the nin one binding protein. *Oncol Rep*. 2015;33(5):2309–18.

41. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. *Biochem Pharmacol.* 2010;79(6):817–24.
42. Sun C, Huang C, Li S, Yang C, Xi Y, Wang L, et al. Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. *Oncotarget.* 2016;7(7):8341–59.
43. Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J, Schmittgen T, et al. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. *J Neurosci.* 2009;29(48):15161–8.
44. Du W, Liu X, Chen L, Dou Z, Lei X, Chang L, et al. Targeting the SMO oncogene by miR-326 inhibits glioma biological behaviors and stemness. *Neuro-Oncology.* 2015;17(2):243–53.
45. Wang S, Lu S, Geng S, Ma S, Liang Z, Jiao B. Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma. *Med Oncol.* 2013;30(1):1–6.
46. Zhou J, Xu T, Yan Y, Qin R, Wang H, Zhang X, et al. MicroRNA-326 functions as a tumor suppressor in glioma by targeting the Nin one binding protein (NOB1). *PLoS One.* 2013;8(7):e68469.
47. Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. *J Transl Med.* 2013;11(10):10–1186.
48. Parathath SR, Mainwaring LA, Fernandez-L A, Guldal CG, Nahlé Z, Kenney AM. β -Arrestin-1 links mitogenic sonic hedgehog signaling to the cell cycle exit machinery in neural precursors. *Cell Cycle.* 2010;9(19):4013–24.
49. Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, et al. A nuclear function of β -arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. *Cell.* 2005;123(5):833–47.
50. Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, et al. ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors. *J Natl Cancer Inst.* 2011;103(4):317–33.
51. Qin R, Li K, Qi X, Zhou X, Wang L, Zhang P, et al. β -Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation. *Br J Cancer.* 2014;111(3):568–76.
52. Mazzà D, Infante P, Colicchia V, Greco A, Alfonsi R, Siler M, et al. PCAF ubiquitin ligase activity inhibits Hedgehog/Gli1 signaling in p53-dependent response to genotoxic stress. *Cell Death Differ.* 2013;20(12):1688–97.
53. Poppy Roworth A, Ghari F, La Thangue NB. To live or let die—complexity within the E2F1 pathway. *Mol Cell Oncol.* 2015;2(1):e970480.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

